Skip to main content
. Author manuscript; available in PMC: 2012 Apr 1.
Published in final edited form as: Menopause. 2011 Apr;18(4):359–365. doi: 10.1097/gme.0b013e3181f7a17a

Figure 3.

Figure 3

Changes in glabellar cutaneous vascular conductance (CVC) at control and botulinum toxin type A (BTX) treated sites during hot flashes from protocol 2. #signifies significant difference between control and BTX-treated areas (P < 0.05). Data are expressed as a percentage change from pre-hot flash baseline.